Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients
Open Access
- 14 October 2010
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 25 (1), 82-88
- https://doi.org/10.1038/leu.2010.234
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Outcome of Transplantation for MyelofibrosisTransplantation and Cellular Therapy, 2010
- Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing actBone Marrow Transplantation, 2010
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)Blood, 2010
- The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in JapanEuropean Journal of Haematology, 2009
- New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and TreatmentBlood, 2009
- CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patientsLeukemia, 2009
- Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disordersLeukemia, 2008
- TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patientsLeukemia, 2008
- Choosing between stem cell therapy and drugs in myelofibrosisLeukemia, 2008
- JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trialsLeukemia, 2007